ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2012
Introducing parametric fusion PET/MRI of primary prostate cancer.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 78 citations in OpenAlex.
- Trial
- 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Trial
- Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma.European radiology · 2014Trial
- Value of fused 18F-Choline-PET/MRI to evaluate prostate cancer relapse in patients showing biochemical recurrence after EBRT: preliminary results.BioMed research international · 2014Trial
- Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics.International journal of molecular sciences · 2022Review
- MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review.Translational andrology and urology · 2021Review
- The impact of the co-registration technique and analysis methodology in comparison studies between advanced imaging modalities and whole-mount-histology reference in primary prostate cancer.Scientific reports · 2021Article
- Advances in Imaging in Prostate and Bladder Cancer.Current urology reports · 2017Review
- Comparison of PET/CT and whole-mount histopathology sections of the human prostate: a new strategy for voxel-wise evaluation.EJNMMI physics · 2017Article
- Preclinical Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
- Contrast-enhanced dual mode imaging: photoacoustic imaging plus more.Biomedical engineering letters · 2017Review
- Metabolic Imaging in Prostate Cancer: Where We Are.Frontiers in oncology · 2016Review
- [Multiparametric imaging with simultaneous MRI/PET: Methodological aspects and possible clinical applications].Zeitschrift fur Rheumatologie · 2015Review
- PET/MRI in Oncological Imaging: State of the Art.Diagnostics (Basel, Switzerland) · 2015Review
- Article
- New prospects for PET in prostate cancer imaging: a physicist's viewpoint.EJNMMI physics · 2014Article
- Potential of hybrid ¹⁸F-fluorocholine PET/MRI for prostate cancer imaging.European journal of nuclear medicine and molecular imaging · 2014Article
- Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.European journal of nuclear medicine and molecular imaging · 2014Article
- Simultaneous PET/MRI: Impact on cancer management-A comprehensive review of cases.The Indian journal of radiology & imaging · 2014Article
- Competitive advantage of PET/MRI.European journal of radiology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledWe assessed the performance of parametric fusion PET/MRI based on (11)C-choline PET/CT and apparent diffusion coefficient (ADC) maps derived from diffusion-weighted MRI for the identification of primary prostate cancer.
methods(11)C-choline PET/CT and MRI were performed in 17 patients with untreated primary prostate cancer, followed by prostatectomy. Registration of in vivo imaging with histology was achieved using a mutual-information objective function and by performing ex vivo MRI of the prostatectomy specimen (obtained at 3 T) and whole-mount sectioning with block-face photography as intermediate steps. Data analysis included volumetrically registered whole-mount histology with Gleason scoring, (11)C-choline, and ADC data (obtained at 1.5 T). Volumes of interest were defined on the basis of histologically proven tumor tissue to calculate tumor-to-benign prostate background ratios (TBRs) for (11)C-choline, ADC, and a derived fusion PET/MRI parameter calculating the quotient of (11)C-choline over ADC (P(CHOL/ADC)).
resultsFifty-one tumor nodules were identified at pathology. The TBRs for (11)C-choline (P < 0.05) and P(CHOL/ADC) (P < 0.005) were significantly higher in prostate cancers with a Gleason score of ≥3 + 4 than with a Gleason score of ≤3 + 3 disease and controls. For Gleason ≥ 3 + 4, the ADC TBRs were significantly lower than controls and Gleason ≤ 3 + 3 disease (P < 0.05). The absolute value of TBRs obtained from Gleason ≥ 3 + 4 cancers increased from ADC to (11)C-choline PET/CT and from (11)C-choline PET/CT to P(CHOL/ADC), with each step being statistically significant.
conclusionOur data indicate that parametric PET/MRI using P(CHOL/ADC) improves lesion-to-background contrast (TBRs) of Gleason ≥ 3 + 4 disease, compared with (11)C-choline PET/CT or diffusion-weighted MRI, and thus hold promise that parametric imaging performed on hybrid PET/MRI may further improve identification and localization of significant primary prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.